Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Sisram Medical Ltd. ( (HK:1696) ) is now available.
Sisram Medical has announced that its sublicensed botulinum toxin type A injectable, DAXXIFY (DaxibotulinumtoxinA-lanm), for treating moderate to severe glabellar lines in adults, has passed quality testing by China’s National Institutes for Food and Drug Control, confirming compliance with the country’s drug quality, safety and efficacy standards. With no competing DaxibotulinumtoxinA-lanm product yet launched in mainland China and initial commercial orders already secured, the company is beginning commercialization and expects DAXXIFY to broaden its premium injectable portfolio, generate recurring consumables revenue and strengthen its leading position in the global wellness market, while advising investors to exercise caution when trading its securities.
The most recent analyst rating on (HK:1696) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
More about Sisram Medical Ltd.
Sisram Medical Ltd., incorporated in Israel and listed in Hong Kong, operates in the global wellness and medical aesthetics industry, with a focus on devices and injectable products aimed at cosmetic and aesthetic indications for adult patients.
Average Trading Volume: 556,205
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.01B
For detailed information about 1696 stock, go to TipRanks’ Stock Analysis page.